Shawn O’Connor: My view has always been that we can grow at or above market growth. And the basket of goods and services that are included in most of your computational biology research reports, we don’t play in all of the markets under that umbrella. So, there are some differences in terms of how you slice the pie there. But generally, if you look back historically, we’ve been able to grow at or above the market and supplant that with acquisitions that then become part of our organic growth in the long run.
François Brisebois: Okay. And in terms of the ratio there, the Software to Services, obviously, the Immunetrics kind of gives a little more of a push on the Service side. What would you ultimately — down the road, can you help us understand where you would like to be in terms of that ratio?
Shawn O’Connor: Well, 60-40 has been our mantra pretty consistently, and I hold to that at this point in time. I think it’s important to — that is the input to top-line revenue growth and bottom-line profitability. Obviously, the mix of Software revenues and Service revenues can contribute to that profitability number, those two revenue sources, in different ways. So, we’ve always targeted that sort of split to maintain the profitability. Service opportunities arise, and service opportunities are good ways for us to broaden our support of our clients, I mean, if it fits right into that and create top-line growth opportunities that didn’t exist in the company before. So, there’s always going to be a trade-off over time, but our commitment is to maintain good, high, and above market revenue growth at the top-line and good profitability profile out of the model.
François Brisebois: Great. That’s it for me. Thank you.
Operator: Thank you. Our next question comes from the line of David Larsen with BTIG. Please proceed with your question.
David Larsen: Just a quick follow-up here. It seems like in the deck, some of the divisions maybe were renamed. I just wanted to make sure that that’s the case, like PBPK is Gastro; CPP, Monolix; Cheminformatics, ADMET; QSP, other; and then, CPP would be PKPD; and reg is other. Is that correct or not?
Shawn O’Connor: Yeah, you’ve got two forms of presentation in there, Dave. The business units are the PBPK, the Cheminformatics, the CPP, Clinical Pharmacology Pharmacometrics, and the Regulatory Strategies of the business units. When we report the Software underlying details, GastroPlus is the primary software product in the PBPK business unit. Monolix is the primary software product in CPP, and ADMET Predictor is the primary product in Cheminformatics. So, we’re presenting information that is summarized by business unit as well as summarized by product.
David Larsen: Okay. Fantastic. Thank you. Congrats again.
Shawn O’Connor: Sure.
Operator: Thank you. There are no further questions at this time. I would like to turn the floor back over to Mr. Shawn O’Connor for closing comments.
Shawn O’Connor: Very good. Thank you, operator, and thank all of you for your attention today. Good start to the year by Simulations Plus, and I look forward to reporting continued results next quarter. Take care.
Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.
